Relationship between Chemosensitivity to L-OHP in vitro and Expressions of Multidrug Resistance Associated Factors in Lymph Node Metastases of Gastric Carcinoma
10.3969/j.issn.1000-8179.2009.23.011
- VernacularTitle:胃癌转移淋巴结奥沙利铂体外化疗药敏性与多种耐药相关因子表达的关系
- Author:
Yong LI
;
Bibo TAN
;
Jie HAN
;
Liqiao FAN
;
Qun ZHAO
;
Zhenchuan SONG
;
Dong WANG
- Publication Type:Journal Article
- Keywords:
Gastdc neoplasms;
Lymph node metastasis;
Multidrug resistance associated factors;
Chemosensitivity;
Oxaliplatin (L-OHP)
- From:
Chinese Journal of Clinical Oncology
2009;36(23):1353-1355,1364
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the relationship between chemosensitivity to L-OHP and expressions of multidrug resistance (MDR) associated factors in lymph node metastases (LNMs) of gastric carcinoma. Methods: The chemosensitivity to L-OHP was measured by MIT assay, and the expressions of P-gp, GST-π, P53, Survivin and Bcl-2 were determined by immunohistochemistry in 54 paired primary tumor (PT) and LNMs of gastric carcinoma. Results: The inhibition rates of LNMs cells for L-OHP were lower than those of PT (P<0.05). The expressions of P-gp, GST-π and Bcl-2 were higher in LNMs than in PT (P<0.05), and no signifi-cant difference was found in the expression of P53 and Survivin between LNMs and PT (P>0.05). Positive cor-relations among P-gp, P53 and Bcl-2 were found in PT and LNMs (r=0.3424, 0.7123, 0.4548, P<0.05). There was no significant difference in the expression of GST-π and Survivin between PT and LNMs (P>0.05). There was statistically negative correlation between inhibition rates and expression of P-gp, GST-π, and Survivin in PT (P<0.05). In LNMs, only Survivin was negatively correlated with inhibition rates of L-OHP (P<0.05). Conclu-sion: The LNMs of gastric carcinoma are heterogeneous with PT in respect to chemosensitivity to L-OHP and expression of multidrug resistance associated factors. The main factors that affect chemosensitivity to L-OHP are also significantly different between PT and LNMs. Effective adjuvant chemotherapy after surgery and re-version to multidrug resistance (MDR) of gastric carcinoma depend on targeting the metastatic lesions of gas-tric carcinoma.
